Clinical Trial

Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)

Study acronym: GAP
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2006-09-07; most recent amendment 2025-10-28.
Trial Details
NCT Number NCT00373841
Lead Sponsor University of Pittsburgh
Conditions Idiopathic Pulmonary Fibrosis
Enrollment 500 participants
Start Date 2005-10
Primary Completion 2030-07 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2025-10-29